|Other Names||Ubiquilin-2, Chap1, DSK2 homolog, Protein linking IAP with cytoskeleton 2, PLIC-2, hPLIC-2, Ubiquitin-like product Chap1/Dsk2, UBQLN2, N4BP4, PLIC2|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP2175a was selected from the N-term region of human Dsk2 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Increases the half-life of proteins destined to be degraded by the proteasome; may modulate proteasome-mediated protein degradation.|
|Cellular Location||Cytoplasm. Nucleus. Note=Where it colocalizes with the proteasome. Associated with fibers in mitotic cells|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Dsk2 increases the half-life of proteins destined to be degraded by the proteasome, and may modulate proteasome-mediated protein degradation. The Dsk2 protein binds UBE3A and BTRC, and interacts with the 19S proteasome subunit. In the cytoplasm, Dsk2 colocalizes with the proteasome; it is also associated with fibers in mitotic cells in the nucleus. Dsk2 is highly expressed in mitotic cells from metaphase to telophase, while expression in non-mitotic cells is very low.
Walters, K.J., et al., Biochemistry 41(6):1767-1777 (2002).Kleijnen, M.F., et al., Mol. Cell 6(2):409-419 (2000).Ueki, N., et al., Nat. Biotechnol. 16(13):1338-1342 (1998).
If you have any additional inquiries please email technical services at firstname.lastname@example.org.